Inmune Bio Stock Market Value
| INMB Stock | USD 4.87 0.11 2.31% |
| Symbol | INmune |
INmune Bio Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share 0.002 | Quarterly Revenue Growth (0.63) | Return On Assets (0.45) | Return On Equity (0.99) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
INmune Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to INmune Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of INmune Bio.
| 12/04/2022 |
| 11/23/2024 |
If you would invest 0.00 in INmune Bio on December 4, 2022 and sell it all today you would earn a total of 0.00 from holding INmune Bio or generate 0.0% return on investment in INmune Bio over 720 days. INmune Bio is related to or competes with Eliem Therapeutics, HCW Biologics, RenovoRx, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate i... More
INmune Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure INmune Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess INmune Bio upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.10) | |||
| Maximum Drawdown | 22.66 | |||
| Value At Risk | (7.10) | |||
| Potential Upside | 5.78 |
INmune Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for INmune Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as INmune Bio's standard deviation. In reality, there are many statistical measures that can use INmune Bio historical prices to predict the future INmune Bio's volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.63) | |||
| Total Risk Alpha | (1.03) | |||
| Treynor Ratio | (0.14) |
INmune Bio Backtested Returns
INmune Bio holds Efficiency (Sharpe) Ratio of -0.11, which attests that the entity had a -0.11% return per unit of risk over the last 3 months. INmune Bio exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out INmune Bio's Market Risk Adjusted Performance of (0.13), standard deviation of 4.41, and Risk Adjusted Performance of (0.05) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 2.39, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, INmune Bio will likely underperform. At this point, INmune Bio has a negative expected return of -0.47%. Please make sure to check out INmune Bio's maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if INmune Bio performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.15 |
Insignificant predictability
INmune Bio has insignificant predictability. Overlapping area represents the amount of predictability between INmune Bio time series from 4th of December 2022 to 29th of November 2023 and 29th of November 2023 to 23rd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of INmune Bio price movement. The serial correlation of 0.15 indicates that less than 15.0% of current INmune Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.15 | |
| Spearman Rank Test | 0.0 | |
| Residual Average | 0.0 | |
| Price Variance | 6.58 |
INmune Bio lagged returns against current returns
Autocorrelation, which is INmune Bio stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting INmune Bio's stock expected returns. We can calculate the autocorrelation of INmune Bio returns to help us make a trade decision. For example, suppose you find that INmune Bio has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
INmune Bio regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If INmune Bio stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if INmune Bio stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in INmune Bio stock over time.
Current vs Lagged Prices |
| Timeline |
INmune Bio Lagged Returns
When evaluating INmune Bio's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of INmune Bio stock have on its future price. INmune Bio autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, INmune Bio autocorrelation shows the relationship between INmune Bio stock current value and its past values and can show if there is a momentum factor associated with investing in INmune Bio.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:Check out INmune Bio Correlation, INmune Bio Volatility and INmune Bio Alpha and Beta module to complement your research on INmune Bio. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
INmune Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.